Skip to main content
. 2021 Sep 28;9(10):1339. doi: 10.3390/biomedicines9101339

Figure 3.

Figure 3

CD44NK cells specifically kill primary patient-derived ovarian cancer cells. (A) Flow cytometric analyses of expression levels of CD44 on three different primary ovarian cancer cell samples collected from one patient before chemotherapy (P1) or during chemotherapy (P2 and P3). Cytotoxic effects of engineered NK-92 cells on primary ovarian cancer cells P2 (B), P3 (C), and P1 (D) as measured by xCELLigence. E/T indicates the specific effector/target cell ratios. (E) Sequential microscopic images of the co-culture of CD19NK or CD44NK cells with primary ovarian cancer cells with an E/T ratio of 5:1.